Blackstone group cuts Compass stake to 3.4%
Compass Therapeutics, Inc. (CMPX) received an amended Schedule 13G from a group of Blackstone-related entities reporting a reduced ownership position.
Rhea-AI Filing Summary
Compass Therapeutics, Inc. (CMPX) received an amended Schedule 13G from a group of Blackstone-related entities reporting a reduced ownership position. As of December 31, 2025, the reporting group beneficially owned an aggregate 6,126,182 shares of common stock, representing 3.4% of the class, based on 177,572,498 shares outstanding as of September 30, 2025. Blackstone Annex Master Fund L.P. directly holds 2,447,820 shares, and Spruce Street Aggregator L.P. directly holds 3,678,362 shares. The filing states that, as of that date, the reporting persons no longer beneficially own more than five percent of Compass Therapeutics’ common stock and describes this as an exit filing. The group also certifies that the securities were not acquired to change or influence control of the company and includes standard disclaimers that certain parties may be deemed beneficial owners only through their control of the direct holders.
Positive
- None.
Negative
- None.
Insights
Blackstone-linked holders report CMPX stake reduced to 3.4%, triggering an exit 13G filing.
Several entities affiliated with Blackstone report aggregate beneficial ownership of 6,126,182 shares of Compass Therapeutics common stock, or 3.4% of shares outstanding as of September 30, 2025. Direct holdings sit in Blackstone Annex Master Fund L.P. and Spruce Street Aggregator L.P.
The group discloses that, as of December 31, 2025, it no longer beneficially owns more than 5% of the company, making this an exit filing under Schedule 13G rules. The entities include standard language disclaiming beneficial ownership except to the extent they directly hold securities.
The certification states the position is not held for the purpose of changing or influencing control. Actual portfolio impact depends on how these ownership changes compare with prior positions, which is not detailed in this excerpt, so the information mainly updates public float and large-holder visibility.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Why is this Schedule 13G/A for Compass Therapeutics (CMPX) described as an exit filing?
How was the ownership percentage in Compass Therapeutics (CMPX) calculated in this 13G/A?
Do the Blackstone reporting persons seek to influence control of Compass Therapeutics (CMPX)?
Who signed the Compass Therapeutics (CMPX) Schedule 13G/A on behalf of the Blackstone entities?
AI-generated analysis. How Rhea-AI works. Not financial advice.